As of November 6, 2026, Soligenix, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 12, 2026 (Form 8-K, June 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Soligenix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Soligenix, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-12. Every row below is cited to the filing it comes from, and this page adds each new change as Soligenix, Inc. files it.
Also on the record for Soligenix, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13G/A, by MJL Manager LLC | 9.4% of the class | 5%+ stakes | Source |
| June 25, 2026 | Stake report, Schedule 13G, by Michael Liu | 5.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 6.72% of the class | 5%+ stakes | Source |
| October 1, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Soligenix, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Soligenix, Inc. and the records around it.
Soligenix, Inc. elsewhere on the record
Companies that share a holder
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Soligenix, Inc.
Get an email when Soligenix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Soligenix, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Soligenix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Soligenix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-12 | Reported | not named in the filing | 8-K, 2026-06-12 |
New leaders reset buying decisions — get the Full Report on Soligenix, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Soligenix, Inc., with the record behind each one.
Find candidates like senior executive at Soligenix, Inc.Every change, in the filing's words
Reported
On June 11, 2026, in connection with the Company's decision to terminate the HyBryte development program as described under
- As previously disclosed, Richard C. Straube, MD, retired from his employment as Chief Medical Officer and Senior Vice President of Soligenix, Inc. (the "Company") effective August 12, 2025 and entered into a one-year consulting agreement (the "Consulting Agreement"), pursuant to which Dr. Straube served as the Company's Consulting Chief Medical Officer effective August 16, 2025.
- Under the Consulting Agreement, Dr. Straube served as an independent contractor and received an hourly consulting fee of $1,000 per hour for up to ten hours per month of consulting work.
Tools for this story
Each opens in a new tab, filled in for Soligenix, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.